Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs ASTRAZENECA PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES ASTRAZENECA PHARMA DIVIS LABORATORIES/
ASTRAZENECA PHARMA
 
P/E (TTM) x 60.4 152.3 39.7% View Chart
P/BV x 13.9 42.8 32.5% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 DIVIS LABORATORIES   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
ASTRAZENECA PHARMA
Mar-18
DIVIS LABORATORIES/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,6391,278 128.3%   
Low Rs1,115883 126.3%   
Sales per share (Unadj.) Rs186.3228.4 81.6%  
Earnings per share (Unadj.) Rs51.010.4 491.7%  
Cash flow per share (Unadj.) Rs57.316.3 352.5%  
Dividends per share (Unadj.) Rs16.000-  
Dividend yield (eoy) %1.20-  
Book value per share (Unadj.) Rs261.898.8 265.0%  
Shares outstanding (eoy) m265.4725.00 1,061.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.44.7 156.3%   
Avg P/E ratio x27.0104.2 25.9%  
P/CF ratio (eoy) x24.066.4 36.2%  
Price / Book Value ratio x5.310.9 48.1%  
Dividend payout %31.40-   
Avg Mkt Cap Rs m365,59227,008 1,353.7%   
No. of employees `00011.81.4 873.7%   
Total wages/salary Rs m5,4231,535 353.2%   
Avg. sales/employee Rs Th4,175.14,210.9 99.1%   
Avg. wages/employee Rs Th457.71,132.2 40.4%   
Avg. net profit/employee Rs Th1,141.8191.1 597.6%   
INCOME DATA
Net Sales Rs m49,4635,710 866.2%  
Other income Rs m1,556123 1,270.4%   
Total revenues Rs m51,0195,833 874.7%   
Gross profit Rs m18,718463 4,043.7%  
Depreciation Rs m1,689147 1,145.9%   
Interest Rs m350-   
Profit before tax Rs m18,551438 4,235.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,023179 2,807.9%   
Profit after tax Rs m13,527259 5,220.9%  
Gross profit margin %37.88.1 466.8%  
Effective tax rate %27.140.8 66.3%   
Net profit margin %27.34.5 602.7%  
BALANCE SHEET DATA
Current assets Rs m46,5013,209 1,449.0%   
Current liabilities Rs m8,4682,070 409.2%   
Net working cap to sales %76.920.0 385.2%  
Current ratio x5.51.6 354.1%  
Inventory Days Days13172 180.8%  
Debtors Days Days8635 245.8%  
Net fixed assets Rs m25,797790 3,264.2%   
Share capital Rs m53150 1,061.8%   
"Free" reserves Rs m68,9622,419 2,850.5%   
Net worth Rs m69,4932,469 2,814.3%   
Long term debt Rs m00-   
Total assets Rs m80,3834,605 1,745.4%  
Interest coverage x531.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.61.2 49.6%   
Return on assets %16.95.6 299.9%  
Return on equity %19.510.5 185.5%  
Return on capital %26.717.7 150.8%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,238300 13,766.5%   
Fx outflow Rs m12,4052,015 615.7%   
Net fx Rs m28,833-1,715 -1,680.8%   
CASH FLOW
From Operations Rs m9,54388 10,856.7%  
From Investments Rs m-6,854-94 7,322.6%  
From Financial Activity Rs m-2,459NA-  
Net Cashflow Rs m230-6 -4,028.1%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 11.8 0.3 3,933.3%  
FIIs % 19.0 15.7 121.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 9.1 189.0%  
Shareholders   31,796 12,856 247.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SANOFI INDIA  TORRENT PHARMA  STRIDES PHARMA SCIENCE  CIPLA  ABBOTT INDIA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Fell Over 1% Today(Closing)

Indian share markets witnessed heavy selling pressure today, pausing the record rally, with all sectors barring telecom, reeling under pressure.

Related Views on News

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY21); Net Profit Down 13.4% (Quarterly Result Update)

Sep 22, 2020 | Updated on Sep 22, 2020

For the quarter ended June 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 186 m (down 13.4% YoY). Sales on the other hand came in at Rs 2 bn (down 5.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY20); Net Profit Down 2.5% (Quarterly Result Update)

May 20, 2020 | Updated on May 20, 2020

For the quarter ended March 2020, ASTRAZENECA PHARMA has posted a net profit of Rs 96 m (down 2.5% YoY). Sales on the other hand came in at Rs 2 bn (up 2.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

Five Wishes and a Will(The Honest Truth)

Jan 4, 2021

Ajit Dayal on the investing strategy for 2021 and beyond.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Jan 15, 2021 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS